RNA
Atrium Therapeutics, Inc. NASDAQ Listed Feb 27, 2026$12.96
Mkt Cap $201.1M
52w Low $11.95
21.0% of range
52w High $16.77
50d MA $13.76
200d MA $13.76
P/E (TTM)
-3.0x
EV/EBITDA
0.2x
P/B
1.1x
Debt/Equity
0.0x
ROE
-40.5%
P/FCF
-5.9x
RSI (14)
—
ATR (14)
—
Beta
0.00
50d MA
$13.76
200d MA
$13.76
Avg Volume
922.2K
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
10578 Science Center Drive · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -1.24 | -0.61 | +50.8% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 11 | Chardan Capital | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Oct 29 | TD Cowen | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Oct 28 | Chardan Capital | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Oct 28 | RBC Capital | Downgrade | Outperform → Sector Perform | — | — | — | — | — | — | — | — | — |
| Oct 27 | Bernstein | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Oct 27 | Raymond James | Downgrade | Strong Buy → Market Perform | — | — | — | — | — | — | — | — | — |
| Oct 27 | Needham | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Oct 27 | Leerink Partners | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Oct 27 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Oct 27 | Citigroup | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Sep 22 | Evercore ISI | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Sep 15 | BofA Securities | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 10 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 10 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 8 | Barclays | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Aug 8 | Wells Fargo | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Jun 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Jun 10 | Citigroup | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 10 | Barclays | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Jun 9 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 9 | BofA Securities | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 7 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 9 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 17 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 17 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 10 | BofA Securities | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Feb 28 | Barclays | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Feb 28 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 13 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 31 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 30 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 21 | TD Cowen | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Sep 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Aug 26 | Evercore ISI | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Aug 13 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 12 | Evercore ISI | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Aug 9 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 13 | BofA Securities | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 12 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K · 5.02
!!! Very High
Atrium Therapeutics, Inc. -- 8-K 5.02: Executive Change
Atrium Therapeutics appointed four new directors following its distribution from Bristol Myers Squibb, signaling completion of the planned spinoff and establishment of independent board governance.
Feb 27
8-K · 5.02
!!! Very High
Atrium Therapeutics, Inc. -- 8-K 5.02: Executive Change
Novartis's acquisition of Atrium Therapeutics closed at $72.00 per share, providing value to optionholders whose stock options exceeded the exercise price.
Feb 27
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
Atrium Therapeutics completed a spin-off from its parent company, creating an independent entity focused on its therapeutic pipeline with separate ownership structure and operational autonomy.
Feb 26
8-K · 7.01
! Medium
Atrium Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Avidity Biosciences plans to distribute all Atrium Therapeutics shares pro rata to its stockholders, creating a spinoff that will give Avidity investors direct ownership in the independent company.
Feb 26
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
Novartis's acquisition of Atrium Therapeutics (RNA) through Avidity Biosciences is progressing toward shareholder vote, with the definitive proxy statement filed January 30, 2026.
Feb 23
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
This filing appears to contain standard forward-looking statement disclaimers rather than material news, providing limited actionable information for investors regarding Atrium Therapeutics' operations or financial condition.
Feb 3
Data updated apr 26, 2026 11:11pm
· Source: massive.com